OpenAI launches new AI model for life sciences research - Axios

So OpenAI, fresh from planting its flag in London and watching Anthropic release a 'strategically safeguarded' Opus model, has decided the best way to demonstrate responsible AI development is to launch a series of models specifically designed for life sciences research. GPT-Rosalind, named after the scientist whose work was famously exploited without credit, is being pitched as a tool for 'fundamental reasoning' in biochemistry and genomics. Because what could possibly go wrong when you give AI models trained on biological data to researchers who are already warning about their potential misuse for designing dangerous pathogens?

Of course, the announcement comes with the usual corporate gloss: this is about 'helping life sciences researchers work faster,' not about creating the world's most accessible bioweapon design assistant. OpenAI's timing is impeccable, releasing this just as the safety community is sounding alarms about the very capabilities they're now commercializing. The company that once warned about AGI risks is now selling specialized tools that could accelerate the very research pathways they claimed to be worried about – all while maintaining the cheerful fiction that 'responsible deployment' will somehow prevent misuse.

This is the same pattern we saw with Anthropic's Mythos model – create something potentially dangerous, get spooked by your own creation, then release a slightly less dangerous version while expanding your global footprint. The regulatory gap here is particularly glaring: while governments are still debating basic AI safety frameworks, companies are already building tools that could reshape biological research in ways we don't fully understand. OpenAI's move into life sciences isn't innovation – it's regulatory arbitrage, dressed up as scientific progress while researchers warn about the very risks they're now monetizing.